` BLU (BELLUS Health Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

BLU
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, BLU has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +21% growth.

Stocks Performance
BLU vs S&P TSX Composite Index (Canada)

Loading
BLU
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
BLU vs S&P TSX Composite Index (Canada)

Loading
BLU
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
BLU vs S&P TSX Composite Index (Canada)

Loading
BLU
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
BELLUS Health Inc vs Peers

S&P TSX Composite Index (Canada)
BLU
ABBV
CYTH
AMGN
GILD
Add Stock

BELLUS Health Inc
Glance View

Market Cap
2.5B CAD
Industry
Biotechnology

BELLUS Health Inc., a biopharmaceutical company headquartered in Laval, Canada, has carved a niche for itself within the competitive landscape of drug development by focusing on addressing unmet medical needs, particularly within the domain of chronic cough. Its flagship product, BLU-5937, is a novel treatment under development intended to provide relief for millions of patients suffering from chronic refractory cough—a condition often overlooked by traditional pharmaceutical giants. The potential value of this compound lies in its unique mechanism as a P2X3 antagonist, which is designed to specifically target and alleviate cough symptoms without compromising the patient's sense of taste, a common side effect seen in previous attempts by other companies targeting the same receptor. The firm's strategic pathway to profitability revolves around the clinical success and eventual commercialization of BLU-5937. BELLUS Health has invested heavily in clinical trials to establish the compound’s efficacy and safety, navigating through the stringent phases mandated by health regulatory bodies such as the FDA. By achieving favorable trial results, the company positions itself advantageously for partnerships or acquisitions, often considered lucrative exits or expansion opportunities within the biotech industry. Revenue generation, at this juncture, primarily hinges on these strategic partnerships, where the promise of innovative, less invasive treatment alternatives to unmet health needs can potentially lead to substantial future royalties, milestone payments, and licensing deals, ensuring a lucrative return for BELLUS and its stakeholders.

BLU Intrinsic Value
Not Available
Back to Top